Related Experiment Video
Updated: Feb 15, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
Does the use of melatonin overcome drug resistance in cancer chemotherapy?
Mohammad Hossein Asghari1, Emad Ghobadi2, Milad Moloudizargari3
1Department of Pharmacology, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran.
Abstract:
Our knowledge regarding the implications of melatonin in the therapy of numerous medical conditions, including cancer is constantly expanding. Melatonin can variably affect cancer pathology via targeting several key aspects of any neoplastic condition, including the very onset of carcinogenesis as well as tumor growth, differentiation, and dissemination. Numerous studies have examined the effects of melatonin in the context of various cancers reporting the enhanced efficacy of chemo/radiotherapy in combination with this compound. Reduced sensitivity and also resistance of cancer cells to antineoplastic agents are common events which might arise as a result of genomic instability of the malignant cells. Genetic mutations provide numerous mechanisms for these cells to resist cytotoxic therapies. Melatonin, due to its pleitropic effects, is able to correct these alterations in favour of sensitization to antineoplastic agents as evident by increased response to treatment via modulating the expression and phosphorylation status of drug targets, the reduced clearance of drugs by affecting their metabolism and transport within the body, decreased survival of malignant cells via altering DNA repair and telomerase activity, and enhanced responsiveness to cell death-associated mechanisms such as apoptosis and autophagy. These effects are presumably governed by melatonin's interventions in the main signal transduction pathways such as Akt and MAPK, independent of its antioxidant properties. Possessing such a signaling altering nature, melatonin can considerably affect the drug-resistance mechanisms employed by the malignant cells in breast, lung, hepatic, and colon cancers as well as different types of leukemia which are the subject of the current review.
Insights
Melatonin enhances cancer therapy by overcoming drug resistance through multiple cellular mechanisms. This compound improves chemotherapy and radiotherapy efficacy in various cancers, including breast, lung, and leukemia.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Melatonin's role in cancer therapy is increasingly recognized.
- Cancer cells develop resistance to treatments like chemotherapy and radiotherapy.
- Melatonin exhibits pleiotropic effects impacting carcinogenesis, tumor growth, and metastasis.
Purpose of the Study:
- To review the multifaceted effects of melatonin in cancer treatment.
- To explore how melatonin can overcome drug resistance in various cancers.
- To highlight melatonin's potential to enhance conventional cancer therapies.
Main Methods:
- Review of existing studies on melatonin and cancer.
- Analysis of melatonin's impact on cancer cell signaling pathways.
- Investigation of melatonin's influence on drug metabolism and DNA repair.
Main Results:
- Melatonin enhances chemo/radiotherapy efficacy across multiple cancer types.
- It sensitizes resistant cancer cells by modulating drug targets and reducing drug clearance.
- Melatonin influences DNA repair, telomerase activity, apoptosis, and autophagy.
Conclusions:
- Melatonin effectively combats cancer drug resistance through various mechanisms.
- It modulates key signaling pathways (Akt, MAPK) independently of its antioxidant properties.
- Melatonin holds significant potential for improving treatment outcomes in breast, lung, hepatic, colon cancers, and leukemia.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Resistivity
Resistance
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Equivalent Resistance

